Abstract
Over the past 20 years, studies of transient receptor potential (TRP) channels have significantly extended our knowledge regarding the molecular basis of Ca2+ signals in cardiac myocytes. The functional significance of cardiac TRP channels is likely connected to the alteration of membrane potential or Ca2+ entry into a noncontractile compartment, where gene expression responsible for various cardiac diseases is induced. This review highlights some aspects of TRP channels with anticipated roles in cardiac disease. Evidence suggests that (a) increased activities of TRPC1, TRPC3, or TRPC6 are involved in the development of cardiac hypertrophy, where these TRPC channels act as unique sensors for a wide range of hypertrophic stimuli, and (b) mutations in TRPM4 are now recognized as causes of human cardiac conduction disorders. Ultimately, TRP channels may become novel pharmacological targets in the treatment of human cardiac disease.
Keywords: Cardiac arrhythmia, cardiac hypertrophy, Orai1, Stim1, TRPC1, TRPC3, TRPC6, TRPM4
Current Topics in Medicinal Chemistry
Title:Possible Involvement of TRP Channels in Cardiac Hypertrophy and Arrhythmia
Volume: 13 Issue: 3
Author(s): Hiroyuki Watanabe, Kenji Iino, Takayoshi Ohba and Hiroshi Ito
Affiliation:
Keywords: Cardiac arrhythmia, cardiac hypertrophy, Orai1, Stim1, TRPC1, TRPC3, TRPC6, TRPM4
Abstract: Over the past 20 years, studies of transient receptor potential (TRP) channels have significantly extended our knowledge regarding the molecular basis of Ca2+ signals in cardiac myocytes. The functional significance of cardiac TRP channels is likely connected to the alteration of membrane potential or Ca2+ entry into a noncontractile compartment, where gene expression responsible for various cardiac diseases is induced. This review highlights some aspects of TRP channels with anticipated roles in cardiac disease. Evidence suggests that (a) increased activities of TRPC1, TRPC3, or TRPC6 are involved in the development of cardiac hypertrophy, where these TRPC channels act as unique sensors for a wide range of hypertrophic stimuli, and (b) mutations in TRPM4 are now recognized as causes of human cardiac conduction disorders. Ultimately, TRP channels may become novel pharmacological targets in the treatment of human cardiac disease.
Export Options
About this article
Cite this article as:
Watanabe Hiroyuki, Iino Kenji, Ohba Takayoshi and Ito Hiroshi, Possible Involvement of TRP Channels in Cardiac Hypertrophy and Arrhythmia, Current Topics in Medicinal Chemistry 2013; 13 (3) . https://dx.doi.org/10.2174/1568026611313030006
DOI https://dx.doi.org/10.2174/1568026611313030006 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advance in the Pharmacology of Dihydropyrimidinone
Mini-Reviews in Medicinal Chemistry Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy
Cardiovascular & Hematological Disorders-Drug Targets The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews How to Achieve Near Zero Fluoroscopy During Radiofrequency Ablation of Atrial Fibrillation: A Strategy Used at Two Centers
Current Cardiology Reviews COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?
Current Pharmaceutical Design Mexiletine Metabolites: A Review
Current Medicinal Chemistry Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design A Review of Dietary Influences on Cardiovascular Health: Part 1: the role of Dietary Nutrients
Cardiovascular & Hematological Disorders-Drug Targets Computational and Functional Analysis of the Androgen Receptor Antagonist Atraric Acid and Its Derivatives
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Toxicity from the Perspective of Oxidative Stress, Electron Transfer, and Prevention by Antioxidants
Current Vascular Pharmacology Subject Index to Volume 10
Current Pharmaceutical Design Hypertension in 2017: Update in Treatment and Pharmaceutical Innovations
Current Pharmaceutical Design The Progress Towards the Development of DHQO Derivatives and Related Analogues with Inotropic Effects
Mini-Reviews in Medicinal Chemistry Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design Arrhythmia Pharmacogenomics: Methodological Considerations
Current Pharmaceutical Design Diabetes Mellitus, Hypertension and Hypercholesterolemia in Relation to the 10-Year ACS Prognosis; the GREECS Study
Current Vascular Pharmacology Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry